RSV MEDI deltaM2-2

Drug Profile

RSV MEDI deltaM2-2

Alternative Names: M2-2 RSV vaccine - Medimmune; Medi RSV M2-2 vaccine; Medi-RSV-delta-M2-2 vaccine; Respiratory-syncytial virus vaccine M2-2 – Medimmune; RSV MEDI deltaM2-2 vaccine; RSV vaccine intranasal - Medimmune

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Institute of Allergy and Infectious Diseases
  • Developer MedImmune; National Institute of Allergy and Infectious Diseases
  • Class Attenuated vaccines; DNA vaccines; Respiratory syncytial virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Respiratory syncytial virus infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(In children, In infants, Prevention, In adults) in USA (Intranasal, Drops)
  • 01 Aug 2011 Phase-I clinical trials in Respiratory syncytial virus infections (prevention in infants, children and adults) in USA (Intranasal)
  • 01 Jan 2000 Preclinical trials in Respiratory syncytial virus infections in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top